Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: Are we there yet?

Atrial fibrillation (AF) is the most prevalent arrhythmia and is projected to rise from 2.7 –6.1 million in 2010 to 12.1 million by 2030 [1]. AF portends a 4–5 fold risk of ischemic stroke in non-anticoagulated patients, and is an independent risk factor for ischemic stroke severity, recurrence, and mortality [1]. Due to the alarming increase in global prevalence with the attached incr ease in morbidity, mortality, and cost there has been increased effort to identify risk factors in the hope that prevention would turn the tide of this disease [1,2].
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research